Jove
Visualize
Contact Us

Related Experiment Videos

A rheumatologist's viewpoint.

I Stroehmann1

  • 1University of Bonn, West Germany.

European Journal of Rheumatology and Inflammation
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Balancing anti-inflammatory drug effectiveness with reduced gastrointestinal risks is crucial. Nabumetone shows promise, with most patients, even those with dyspepsia history, tolerating it well, suggesting it as a viable option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Not Available].

MMW Fortschritte der Medizin·2016
Same author

[Back pain: guidelines for drug therapy. Utilize the therapeutic spectrum].

MMW Fortschritte der Medizin·2000
Same author

[The established rheumatologist in the tension field between health care deficits and cost control in public health].

Zeitschrift fur Rheumatologie·1995
Same author

German drug monitoring studies with nabumetone.

Drugs·1990
Same author

Efficacy and safety of nabumetone in patients with rheumatic diseases. Results of an outpatient study involving 8,865 patients.

Drugs·1990
Same author

Efficacy and safety of nabumetone in 5,421 patients with osteoarthritis of the hip and/or knee joints. A subgroup evaluation of an outpatient study involving 18,047 patients.

Drugs·1990
Same journal

Double-blind comparison of the efficacy of diclofenac/misoprostol and diclofenac in the treatment of rheumatoid arthritis.

European journal of rheumatology and inflammation·1994
Same journal

Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis.

European journal of rheumatology and inflammation·1994
Same journal

Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee.

European journal of rheumatology and inflammation·1994
Same journal

Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration.

European journal of rheumatology and inflammation·1994
Same journal

Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.

European journal of rheumatology and inflammation·1994
Same journal

Prognostic significance of synovial fluid analysis in estimating the efficacy of intra-articular corticosteroid injection in patients with spondylarthropathy.

European journal of rheumatology and inflammation·1994
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Rheumatology

Background:

  • Prescribing anti-inflammatory drugs (NSAIDs) requires balancing efficacy with reduced risks of serious adverse reactions, particularly upper gastrointestinal (GI) issues.
  • Differences exist among NSAIDs regarding their propensity to cause significant GI problems.
  • Patient-specific risk factors for upper GI side-effects include sex, age, dyspepsia history, comorbidities, and arthritis type.

Purpose of the Study:

  • To evaluate the safety and tolerability of nabumetone in post-marketing surveillance.
  • To identify patient profiles and risk factors associated with adverse reactions to nabumetone.

Main Methods:

  • Post-marketing surveillance studies were conducted in the United Kingdom and Federal Republic of Germany.

Related Experiment Videos

  • Data collected on patient demographics, medical history, drug adherence, and adverse events.

    • Main Results:

    • While patients with a history of dyspepsia were more likely to discontinue nabumetone due to adverse reactions, most tolerated it well.
    • Patients with rheumatoid arthritis showed a higher tendency to stop therapy due to side-effects, though the cause (disease vs. multi-morbidity) was unclear.
    • Nabumetone demonstrated a favorable safety profile in a large patient population.

    Conclusions:

    • Prescribing strategies for NSAIDs should consider patient-specific factors, disease type, and drug characteristics.
    • Nabumetone may be a suitable option for many patients, offering a balance between effectiveness and reduced GI risks.
    • Further investigation into rheumatoid arthritis patients' side-effect profiles is warranted.